Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
pharmacology, toxicology and pharmaceutics
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes
Therapeutic Advances in Psychopharmacology, Volume 10, Year 2020
Notification
URL copied to clipboard!
Description
Background: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (PP1M). This exploratory post hoc subgroup analysis of the 52-week, phase 3b REMISSIO study analysed outcomes according to patient age and disease duration in a naturalistic clinical setting. Methods: Outcomes of patients with schizophrenia were analysed according to age [<35 years (n = 123) versus ⩾35 years (n = 182)] and disease duration [⩽3 years (n = 72) versus >3 years (n = 233)]. The primary efficacy outcome was the proportion of patients achieving symptomatic remission according to the Andreasen criteria. Adverse events were monitored throughout the study. Results: At endpoint (last observation carried forward), 60.7% (95% CI: 51.4%, 69.4%) of younger patients and 54.1% of older patients (95% CI: 46.6%, 61.6%) achieved symptomatic remission. The proportions for patients with disease duration ⩽3 years and >3 years were similar: 57.8% (45.4%, 69.4%) versus 56.5% (49.8%, 62.9%). Functional remission was reached by 45.4% (36.2%, 54.8%) of patients aged <35 years and 36% (28.9%, 43.6%) of patients aged ⩾35 years with a similar pattern when analysed by disease duration. PP3M had a favourable safety profile and was generally well tolerated in both age groups. Conclusion: Patients with schizophrenia, previously stabilized on PP1M, may benefit from PP3M treatment with some additional potential improvements if started early in the disease course. Clinical trials.gov: NCT02713282 © The Author(s), 2020.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC8851108/bin/sj-pdf-1-tpp-10.1177_2045125320981500.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC8851108/bin/sj-pdf-2-tpp-10.1177_2045125320981500.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC8851108/bin/sj-pdf-3-tpp-10.1177_2045125320981500.pdf
Authors & Co-Authors
Bozikas, Vasilis Panteleimon
Greece, Thessaloniki
Aristotle University of Thessaloniki
Emsley, Robin Alexander
South Africa, Stellenbosch
Stellenbosch University
Llorca, Pierre Michel
France, Clermont-ferrand
Université Clermont Auvergne
Gopal, Srihari
Belgium, Beerse
Janssen Research & Development
Bergmans, Paul
Unknown Affiliation
Statistics
Citations: 3
Authors: 5
Affiliations: 4
Identifiers
Doi:
10.1177/2045125320981500
ISSN:
20451253
Research Areas
Health System And Policy
Mental Health
Study Design
Exploratory Study